A lacuna de segurança em longo prazo das novas terapias tópicas não esteroidais na dermatite atópica pediátrica
DOI:
https://doi.org/10.5281/zenodo.23807703Palavras-chave:
Dermatite Atópica. Criança. Segurança dos Medicamentos. Tratamento Farmacológico. Farmacovigilância.Resumo
A dermatite atópica pediátrica frequentemente requer tratamento tópico recorrente, tornando essencial distinguir a boa tolerabilidade observada em ensaios clínicos da segurança demonstrada após exposições cumulativas prolongadas. O objetivo desta revisão foi analisar criticamente as evidências de segurança de crisaborole, roflumilaste, ruxolitinibe, tapinarof, delgocitinibe e difamilaste em crianças e lactentes. Foi desenvolvida revisão narrativa com buscas no SciSpace e verificação complementar de estudos publicados, diretrizes clínicas e documentos regulatórios, com atualização em outubro de 2026. Foram considerados ensaios randomizados, extensões abertas, estudos farmacocinéticos e sínteses da literatura. As evidências incluem acompanhamentos de 48 a 60 semanas, estudos de uso máximo e séries em lactentes, mas alguns resultados derivam de amostras pequenas ou populações etárias mistas (Bissonnette et al., 2025; Igarashi et al., 2026; Saeki et al., 2026). Uma metanálise em rede de 15 ensaios clínicos, abrangendo 3.994 participantes pediátricos, indicou tolerabilidade geral de curto prazo, embora as comparações diretas entre agentes sejam escassas (Yang et al., 2026). Conclui-se que resultados favoráveis durante aproximadamente um ano não permitem excluir eventos raros, efeitos de longa latência ou riscos ligados à exposição plurianual; são necessários estudos pediátricos longitudinais e farmacovigilância estruturada (Davis et al., 2026; Chokshi et al., 2026).
Referências
BISSONNETTE et al. Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitis. Journal of the American Academy of Dermatology, 93(3), 707–714, 2025. DOI: https://doi.org/10.1016/j.jaad.2025.05.1391.
CHOKSHI et al. Topical Janus Kinase Inhibitors for Pediatric Atopic Dermatitis: A Systematic Review of Efficacy and Safety. Pediatric Dermatology, 2026. DOI: https://doi.org/10.1111/pde.70298.
DAVIS et al. Guidelines of care for the management of atopic dermatitis in pediatric patients. Journal of the American Academy of Dermatology, 95(1), 121.e1–121.e26, 2026. DOI: https://doi.org/10.1016/j.jaad.2026.02.113.
EICHENFIELD et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. Journal of the American Academy of Dermatology, 77(4), 641–649.e5, 2017. DOI: https://doi.org/10.1016/j.jaad.2017.06.010.
EICHENFIELD et al. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study. American Journal of Clinical Dermatology, 24(4), 623–635, 2023. DOI: https://doi.org/10.1007/s40257-023-00780-w.
EICHENFIELD et al. Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind study. Journal of the American Academy of Dermatology, 93(3), 689–698, 2025. DOI: https://doi.org/10.1016/j.jaad.2025.05.1385.
EICHENFIELD et al. Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2–5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE). Pediatric Dermatology, 43(3), 642–649, 2026. DOI: https://doi.org/10.1111/pde.70177.
GARG et al. Topical Janus Kinase Inhibitors for Atopic Dermatitis in Children Under 12 Years: A Systematic Review. The Journal of Pediatric Academy, 2026. DOI: https://doi.org/10.4274/jpea.2026.514.
GILLESPIE et al. Emerging topical nonsteroidal therapies in pediatric dermatology: atopic dermatitis, psoriasis, alopecia areata, vitiligo, and seborrheic dermatitis. Current Opinion in Pediatrics, 38(4), 382–388, 2026. DOI: https://doi.org/10.1097/MOP.0000000000001580.
IGARASHI et al. Efficacy and safety of tapinarof cream once daily in Japanese pediatric patients with atopic dermatitis: a 60-week phase 3 trial consisting of an 8-week, double-blind, vehicle-controlled period and a 52-week, open-label extension period. Journal of Cutaneous Immunology and Allergy, 9, Artigo 17307, 2026. DOI: https://doi.org/10.3389/jcia.2026.17307.
JOYCE et al. Safety and Tolerability of Ruxolitinib Cream in Adolescents with Mild-to-Moderate Atopic Dermatitis: Results From a 1-Year, Phase III, Open-Label Study. American Journal of Clinical Dermatology, 27, 841–849, 2026. DOI: https://doi.org/10.1007/s40257-026-01043-0.
NAKAGAWA et al. Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study. Journal of the American Academy of Dermatology, 2021. DOI: https://doi.org/10.1016/j.jaad.2021.06.014.
NAKAGAWA et al. Safety, efficacy, and pharmacokinetics of delgocitinib ointment in infants with atopic dermatitis: A phase 3, open-label, and long-term study. Allergology International, 73(1), 137–142, 2024. DOI: https://doi.org/10.1016/j.alit.2023.04.003.
NATIONAL LIBRARY OF MEDICINE. VTAMA — tapinarof cream: prescribing information (atualização 2025). DailyMed, 2025. Disponível em: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9309d20f-8cd4-4c96-93fa-7f730e83c7ab. Acesso em: 28 out. 2026.
NATIONAL LIBRARY OF MEDICINE. ZORYVE — roflumilast cream: prescribing information (atualização 2026). DailyMed, 2026a. Disponível em: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec1bb0d1-f38a-4080-831a-68791d1d1fdb. Acesso em: 28 out. 2026.
NATIONAL LIBRARY OF MEDICINE. OPZELURA — ruxolitinib cream: prescribing information (atualização de 30 jun. 2026). DailyMed, 2026b. Disponível em: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24da5509-6631-4795-9d42-273faecd08e7. Acesso em: 28 out. 2026.
PAPP et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies. Journal of the American Academy of Dermatology, 88(5), 1008–1016, 2023. DOI: https://doi.org/10.1016/j.jaad.2022.09.060.
SAEKI et al. Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial. British Journal of Dermatology, 186(1), 40–49, 2022. DOI: https://doi.org/10.1111/bjd.20655.
SAEKI et al. A Phase 3, Long-Term, Open-Label Study of Difamilast Ointment to Evaluate Efficacy and Safety in Japanese Infants with Atopic Dermatitis. Dermatology and Therapy (Heidelberg), 16(1), 339–352, 2026. DOI: https://doi.org/10.1007/s13555-025-01581-1.
SCHLESSINGER et al. Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1). American Journal of Clinical Dermatology, 21(2), 275–284, 2020. DOI: https://doi.org/10.1007/s40257-020-00510-6.
SIEGFRIED et al. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatrics, 2016. DOI: https://doi.org/10.1186/s12887-016-0607-9.
SILVERBERG et al. Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. Journal of the American Academy of Dermatology, 91(3), 457–465, 2024. DOI: https://doi.org/10.1016/j.jaad.2024.05.023.
SIMPSON et al. Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial. Dermatitis, 37(1), 75–83, 2026. DOI: https://doi.org/10.1089/derm.2024.0418.
STEIN GOLD et al. A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2–11 Years with Moderate to Severe Atopic Dermatitis. American Journal of Clinical Dermatology, 26(2), 275–289, 2025. DOI: https://doi.org/10.1007/s40257-024-00909-5.
YANG et al. Novel nonsteroidal topical therapies for pediatric atopic dermatitis: a systematic review and network meta-analysis of randomized controlled trials. Frontiers in Immunology, 17, 1906218, 2026. DOI: https://doi.org/10.3389/fimmu.2026.1906218.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2026 Journal of Social Issues and Health Sciences (JSIHS)

Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
